$40.55 Million in Sales Expected for OraSure Technologies (OSUR) This Quarter

Analysts expect OraSure Technologies (NASDAQ:OSUR) to announce $40.55 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for OraSure Technologies’ earnings, with the highest sales estimate coming in at $40.59 million and the lowest estimate coming in at $40.50 million. OraSure Technologies posted sales of $32.55 million during the same quarter last year, which would indicate a positive year over year growth rate of 24.6%. The business is expected to report its next quarterly earnings results after the market closes on Wednesday, May 2nd.

According to Zacks, analysts expect that OraSure Technologies will report full year sales of $180.61 million for the current fiscal year, with estimates ranging from $179.22 million to $182.00 million. For the next year, analysts forecast that the company will post sales of $198.03 million per share, with estimates ranging from $195.06 million to $201.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for OraSure Technologies.

How to Become a New Pot Stock Millionaire

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million for the quarter, compared to analyst estimates of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. OraSure Technologies’s quarterly revenue was up 46.5% compared to the same quarter last year. During the same period last year, the company posted $0.13 EPS.

A number of brokerages recently weighed in on OSUR. BidaskClub lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, April 3rd. Zacks Investment Research raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, December 30th. Canaccord Genuity reaffirmed a “buy” rating and issued a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. Finally, ValuEngine raised shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. OraSure Technologies presently has a consensus rating of “Buy” and an average price target of $22.25.

OraSure Technologies stock traded up $0.50 during midday trading on Monday, reaching $17.30. The company had a trading volume of 484,287 shares, compared to its average volume of 638,394. The firm has a market capitalization of $1,033.10, a PE ratio of 33.92, a P/E/G ratio of 4.98 and a beta of 1.65. OraSure Technologies has a 12-month low of $12.29 and a 12-month high of $23.01.

In other OraSure Technologies news, Director Stephen S. Phd Tang sold 23,333 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $17.97, for a total value of $419,294.01. Following the completion of the sale, the director now owns 59,749 shares in the company, valued at approximately $1,073,689.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Brian Smith sold 20,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $17.97, for a total transaction of $359,400.00. Following the completion of the sale, the executive vice president now owns 28,075 shares of the company’s stock, valued at approximately $504,507.75. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in OraSure Technologies by 2.7% in the 4th quarter. BlackRock Inc. now owns 7,729,515 shares of the medical instruments supplier’s stock valued at $145,778,000 after acquiring an additional 201,251 shares during the last quarter. Millennium Management LLC increased its holdings in shares of OraSure Technologies by 87.9% during the 4th quarter. Millennium Management LLC now owns 1,624,216 shares of the medical instruments supplier’s stock worth $30,633,000 after buying an additional 759,958 shares during the last quarter. Fred Alger Management Inc. acquired a new stake in shares of OraSure Technologies during the 4th quarter worth approximately $20,415,000. Teachers Advisors LLC increased its holdings in shares of OraSure Technologies by 9.0% during the 4th quarter. Teachers Advisors LLC now owns 965,464 shares of the medical instruments supplier’s stock worth $18,209,000 after buying an additional 79,886 shares during the last quarter. Finally, RTW Investments LP increased its holdings in shares of OraSure Technologies by 64.0% during the 4th quarter. RTW Investments LP now owns 878,452 shares of the medical instruments supplier’s stock worth $16,568,000 after buying an additional 342,745 shares during the last quarter. Institutional investors own 92.86% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/17/40-55-million-in-sales-expected-for-orasure-technologies-osur-this-quarter.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply